PubRank

M Brandely

Author PubWeight™ 30.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990 2.67
2 High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995 2.00
3 Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996 1.25
4 Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009 1.03
5 Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000 0.95
6 Immunological mechanisms controlling mycobacterial infections. Bull Eur Physiopathol Respir 1983 0.91
7 High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991 0.88
8 Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009 0.87
9 Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 1992 0.86
10 Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993 0.85
11 Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity. Cancer Immunol Immunother 1989 0.83
12 Effects of suramin on the immune responses to sheep red blood cells in mice. I. In vivo studies. Cell Immunol 1985 0.83
13 Interferon-gamma associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS. Rev Infect Dis 1990 0.82
14 IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol Ther 1992 0.82
15 Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity. Clin Exp Immunol 1990 0.81
16 Comparison between immunopotency tests and specific active or passive acquired resistance against Mycobacterium tuberculosis in mice induced with three different preparations of BCG pasteur vaccine. Clin Exp Immunol 1983 0.81
17 A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma 1998 0.81
18 Effects of suramin on the in vivo antimicrobial resistance against Listeria monocytogenes and Mycobacterium bovis (BCG) in mice. Clin Exp Immunol 1986 0.80
19 Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head Neck 1993 0.79
20 Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 1995 0.79
21 Various strains of BCG vaccine and genetic control of the immune response of mice. Dev Biol Stand 1986 0.79
22 Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology 1990 0.78
23 Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. Cancer 1993 0.78
24 The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 1997 0.78
25 Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2. Eur J Cancer 1992 0.78
26 Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma. Clin Exp Immunol 1990 0.77
27 A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients. Cancer Immunol Immunother 1990 0.77
28 Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma. Eur J Cancer 1993 0.77
29 rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: response and enhancement of further chemosensitivity. Anticancer Res 1999 0.77
30 Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients. J Immunother 1999 0.76
31 Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. Eur Cytokine Netw 1992 0.76
32 Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2. Cancer Immunol Immunother 1994 0.76
33 Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. Br J Cancer 2005 0.75
34 [Occlusive arteriopathy of the circle of Willis with outlined "Moya-Moya" network in a woman with migraine under oral contraception. Regressive course]. Sem Hop 1983 0.75
35 Effects of suramin on the immune responses to sheep red blood cells in mice. II. In vitro studies. Cell Immunol 1985 0.75
36 [Venous compression in retroperitoneal fibrosis. Value of isotopic phlebography]. Presse Med 1983 0.75
37 A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. Leuk Lymphoma 1996 0.75
38 Adjuvant arthritis in rat during pregnancy and lactation. Biomed Pharmacother 1982 0.75
39 Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation. Eur Cytokine Netw 1997 0.75
40 [Rheumatoid arthritis. Treatment of flare-ups with pulse corticosteroids]. Presse Med 1983 0.75
41 [Influence of pregnancy and the hormonal status on rheumatoid arthritis]. Presse Med 1983 0.75
42 Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia. Bone Marrow Transplant 1995 0.75
43 Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study. Bone Marrow Transplant 1991 0.75
44 Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with renal cell carcinoma. Eur Urol 1994 0.75
45 Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on bone marrow leukemic blasts after in vivo administration of high-dose recombinant interleukin-2. J Immunother (1991) 1991 0.75
46 Successful interleukin-2 therapy of advanced cutaneous T-cell lymphoma. Br J Dermatol 1992 0.75
47 Interleukin-2-induced increase of a monoclonal B-cell lymphocytosis. A novel in vivo interleukin-2 effect? Cancer 1992 0.75
48 Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer. J Immunother (1991) 1992 0.75
49 Non-cytotoxic CD4 tumour-infiltrating lymphocytes induce responses in patients with metastatic renal cell carcinoma previously treated with interleukin-2. Eur J Cancer 1995 0.75
50 Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2. Leukemia 1994 0.75
51 Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol 1993 0.75